Viking Therapeutics (VKTX) Operating Income: 2014-2025
Historic Operating Income for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$98.6 million.
- Viking Therapeutics' Operating Income fell 169.62% to -$98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.8 million, marking a year-over-year decrease of 105.15%. This contributed to the annual value of -$150.9 million for FY2024, which is 49.68% down from last year.
- Per Viking Therapeutics' latest filing, its Operating Income stood at -$98.6 million for Q3 2025, which was down 32.17% from -$74.6 million recorded in Q2 2025.
- Viking Therapeutics' Operating Income's 5-year high stood at -$12.5 million during Q4 2021, with a 5-year trough of -$98.6 million in Q3 2025.
- Over the past 3 years, Viking Therapeutics' median Operating Income value was -$34.1 million (recorded in 2024), while the average stood at -$43.7 million.
- Data for Viking Therapeutics' Operating Income shows a maximum YoY slumped of 169.62% (in 2025) over the last 5 years.
- Viking Therapeutics' Operating Income (Quarterly) stood at -$12.5 million in 2021, then tumbled by 62.13% to -$20.3 million in 2022, then slumped by 44.38% to -$29.3 million in 2023, then plummeted by 57.89% to -$46.2 million in 2024, then crashed by 169.62% to -$98.6 million in 2025.
- Its Operating Income stands at -$98.6 million for Q3 2025, versus -$74.6 million for Q2 2025 and -$55.5 million for Q1 2025.